Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
Sekino Y, Oue N, Mukai S, Shigematsu Y, Goto K, Sakamoto N, Sentani K, Hayashi T, Teishima J, Matsubara A, et al. Prostate. 2019 Feb; 79(2):234-242. Epub 2018 Oct 16.